AAAAAA

   
Results: 1-8 |
Results: 8
Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants
Authors: Rennels, MB Edwards, KM Keyserling, HL Reisinger, K Blatter, MM Quataert, SA Madore, DV Chang, I Malinoski, FJ Hackell, JG Paradiso, PR
Citation: Mb. Rennels et al., Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants, PEDIAT INF, 20(2), 2001, pp. 153-159
Maternal immunization: the influence of liability issues on vaccine development
Authors: Paradiso, PR
Citation: Pr. Paradiso, Maternal immunization: the influence of liability issues on vaccine development, VACCINE, 20, 2001, pp. S73-S74
Geographical differences for pneumococcal disease - Reply
Authors: Hausdorff, WP Siber, G Paradiso, PR
Citation: Wp. Hausdorff et al., Geographical differences for pneumococcal disease - Reply, LANCET, 358(9279), 2001, pp. 419-420
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children
Authors: Hausdorff, WP Siber, G Paradiso, PR
Citation: Wp. Hausdorff et al., Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children, LANCET, 357(9260), 2001, pp. 950-952
Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
Authors: Hausdorff, WP Bryant, J Paradiso, PR Siber, GR
Citation: Wp. Hausdorff et al., Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I, CLIN INF D, 30(1), 2000, pp. 100-121
The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II
Authors: Hausdorff, WP Bryant, J Kloek, C Paradiso, PR Siber, GR
Citation: Wp. Hausdorff et al., The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II, CLIN INF D, 30(1), 2000, pp. 122-140
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
Authors: Shinefield, HR Black, S Ray, P Chang, I Lewis, N Fireman, B Hackell, J Paradiso, PR Siber, G Kohberger, R Madore, DV Malinowski, FJ Kimura, A Le, C Landaw, I Aguilar, J Hansen, J
Citation: Hr. Shinefield et al., Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers, PEDIAT INF, 18(9), 1999, pp. 757-763
Pediatric combination vaccines - Clinical issues
Authors: Paradiso, PR Kohberger, R
Citation: Pr. Paradiso et R. Kohberger, Pediatric combination vaccines - Clinical issues, COMBINATION VACCINES, 1999, pp. 95-106
Risultati: 1-8 |